Biotech Values

[DewDiligence]

VEGF for heart disease:

[The part I don’t get is “…without a requirement of incorporation…” in the paragraph below.]

http://biz.yahoo.com/prnews/040908/clw003_1.html
>>
In the Phase IIb trial for severe cardiovascular disease, VEGF- 2 is delivered to the ischemic tissue in the heart muscle in the form of naked DNA plasmid, a non-viral vector. Once administered, the DNA plasmid appears to be taken up and expressed by myocardium near the injection site. Inside the cell, the DNA plasmid then enters the nucleus of the cell without a requirement of incorporation into the genomic DNA. The Phase IIb clinical trial expects to see the effect of the expression of DNA-encoded VEGF-2, which in turn stimulates the growth of new blood vessels by promoting the migration and proliferation of endothelial cells in the heart.
<<